Aclaris Therapeutics
ACRS
133 hedge funds and large institutions have $815M invested in Aclaris Therapeutics in 2021 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 49 increasing their positions, 35 reducing their positions, and 17 closing their positions.
6,826% more call options, than puts
Call options by funds: $2.15M | Put options by funds: $31K
65% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 17
40% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 35
6% more funds holding
Funds holding: 126 → 133 (+7)
0% more funds holding in top 10
Funds holding in top 10: 8 → 8 (0)
1.22% less ownership
Funds ownership: 92.76% → 91.53% (-1.2%)
19% less capital inflows, than outflows
Capital inflows: $86.6M | Capital outflows: $107M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Laurion Capital Management
New York
|
+$9.43M |
| 2 |
Commodore Capital
New York
|
+$7.3M |
| 3 |
OrbiMed
New York
|
+$5.06M |
| 4 |
BVF Inc
San Francisco,
California
|
+$4.89M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$4.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Foresite Capital Management III
Larkspur,
California
|
-$35.2M |
| 2 |
Woodline Partners
San Francisco,
California
|
-$10.7M |
| 3 |
Cormorant Asset Management
Boston,
Massachusetts
|
-$9.09M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$8.52M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$6.28M |
ACRS Hedge Fund Activity: Q4 2021 in Review
133 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q4 2021, worth a combined $815M — down 20% from $1.02B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new ACRS positions and 17 closed out — a net gain of 11 holders — while 49 added to existing stakes and 35 trimmed.
The largest buyer was Laurion Capital Management, adding an estimated $9.43M. The largest seller was Foresite Capital Management III, exiting entirely with an estimated $35.2M sold.
- 133 institutional investors held Aclaris Therapeutics (ACRS) as of Q4 2021, up from 126 in Q3 2021.
- Funds reported $815M of Aclaris Therapeutics stock for Q4 2021, down 20% quarter-over-quarter.
- 28 funds opened new Aclaris Therapeutics positions in Q4 2021 and 17 closed out, a net change of +11 holders.
- The largest Aclaris Therapeutics buyer in Q4 2021 was Laurion Capital Management, an estimated $9.43M added.
- The largest Aclaris Therapeutics seller in Q4 2021 was Foresite Capital Management III, an estimated $35.2M sold.
Based on aggregated 13F filings for Q4 2021.